Cargando…

Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial

OBJECTIVES: To evaluate the safety, pharmacokinetics, and preliminary efficacy of NT-814, a dual neurokinin 1,3 antagonist, in postmenopausal women with vasomotor symptoms (hot flashes). METHODS: We completed a double-blind, randomized, placebo-controlled trial in three US clinical research units in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trower, Mike, Anderson, Richard A., Ballantyne, Elizabeth, Joffe, Hadine, Kerr, Mary, Pawsey, Steve
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott-Raven Publishers 2020
Materias:	Original Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188053/ https://www.ncbi.nlm.nih.gov/pubmed/32068688 http://dx.doi.org/10.1097/GME.0000000000001500

Ejemplares similares

OR11-03 NT-814, a Non-Hormonal Dual Neurokinin 1,3 Receptor Antagonist Markedly Improves Vasomotor Symptoms in Post-Menopausal Women; Results of a Randomised, Double-Blind, Placebo-Controlled, Dose-Finding Study (SWITCH-1)
por: Simon, James, et al.
Publicado: (2020)

Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women
por: Pawsey, Steve, et al.
Publicado: (2021)

SUN-LB58 Repeated Once-Daily Administration of the Non-Hormonal Neurokinin 1,3 Receptor Antagonist NT-814 Reduces LH, Estradiol and Progesterone in Healthy Women
por: Dhillo, Waljit Singh, et al.
Publicado: (2020)

Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)
por: Simon, James A., et al.
Publicado: (2023)

Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal
por: Gompel, Anne, et al.
Publicado: (2023)

Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms
por: Pinkerton, JoAnn V, et al.
Publicado: (2023)

Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause
por: Conklin, Melissa, et al.
Publicado: (2023)

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)
por: Santoro, Nanette, et al.
Publicado: (2020)

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial
por: Vincenzi, Bruno, et al.
Publicado: (2020)

OR33-6 The Neurokinin 3 Receptor Antagonist, Fezolinetant, Is Effective in Treatment of Menopausal Vasomotor Symptoms: A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study
por: Fraser, Graeme, et al.
Publicado: (2019)

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
por: Fraser, Graeme L., et al.
Publicado: (2020)

Vasomotor symptoms in midlife women with incident breast cancer: pink SWAN
por: Gold, Ellen B., et al.
Publicado: (2021)

Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause
por: Pinkerton, JoAnn V., et al.
Publicado: (2015)

Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action
por: Prague, Julia K., et al.
Publicado: (2018)

Neurokinin 1 Receptor Antagonists for Pruritus
por: Alam, Majid, et al.
Publicado: (2021)

Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN
por: Thurston, Rebecca C., et al.
Publicado: (2021)

Neurokinin-1 Receptor Antagonists against Hepatoblastoma
por: Muñoz, Miguel, et al.
Publicado: (2019)

The birth of the middle ages 395-814
por: Moss, H.St. L.B

Sympathetic Skin Response and Vasomotor Symptoms in Postmenopausal Osteoporotic Women
por: Ashraf, Alireza, et al.
Publicado: (2015)

Relationship between vasomotor symptoms and metabolic syndrome in postmenopausal women
por: Sayan, Sena, et al.
Publicado: (2018)

Treating hot flushes with a neurokinin 3 receptor antagonist
por: Prague, Julia K., et al.
Publicado: (2017)

Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men
por: Anderson, Richard A, et al.
Publicado: (2020)

Neurokinin-1 Receptor Antagonist Treatment in Polymicrobial Sepsis: Molecular Insights
por: Hegde, Akhil, et al.
Publicado: (2010)

Neurokinin-1 receptor antagonists: A new revolution in antiretroviral treatment?
por: Grewal, Udhayvir Singh
Publicado: (2016)

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020)

Vasomotor symptoms and the homeostatic model assessment of insulin-resistance in Korean postmenopausal women
por: Kwon, Dae Hui, et al.
Publicado: (2016)

The Neurokinin 1 Receptor Antagonist, Ezlopitant, Reduces Appetitive Responding for Sucrose and Ethanol
por: Steensland, Pia, et al.
Publicado: (2010)

The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting
por: Okafor, Dionne, et al.
Publicado: (2017)

Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)

Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists
por: Schöppe, Jendrik, et al.
Publicado: (2019)

French suites nos. 3-6, BWV 814-817
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1994)

The Serine 814 of TRPC6 Is Phosphorylated under Unstimulated Conditions
por: Bousquet, Simon M., et al.
Publicado: (2011)

Characterization and Correction of Geometric Distortions in 814 Diffusion Weighted Images
por: Treiber, Jeffrey Mark, et al.
Publicado: (2016)

Structural insights into the activation of neurokinin 2 receptor by neurokinin A
por: Sun, Wenjing, et al.
Publicado: (2022)

Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach
por: Muñoz, Miguel, et al.
Publicado: (2016)

Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists
por: Bošnjak, Snežana M., et al.
Publicado: (2017)

Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women
por: Prague, Julia K, et al.
Publicado: (2019)

In silico screening of neurokinin receptor antagonists as a therapeutic strategy for neuroinflammation in Alzheimer’s disease
por: Satarker, Sairaj, et al.
Publicado: (2021)

Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients
por: Robinson, Prema, et al.
Publicado: (2023)

Obesity associates with vasomotor symptoms in postmenopause but with physical symptoms in perimenopause: a cross-sectional study
por: Koo, Seul, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0mn5b9t6d3jjjm73m6olnjfl8p